Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
35.42
-0.39 (-1.09%)
Dec 20, 2024, 4:00 PM EST - Market closed
Agios Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 32.87 | 26.82 | 14.24 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | 36.79% | 88.36% | - | - | - | - | Upgrade
|
| Cost of Revenue | 299.46 | 298.41 | 281.61 | 256.97 | 220.81 | - | Upgrade
|
| Gross Profit | -266.59 | -271.58 | -267.37 | -256.97 | -220.81 | - | Upgrade
|
| Selling, General & Admin | 140.39 | 119.9 | 121.67 | 121.45 | 115.11 | 102.01 | Upgrade
|
| Research & Development | - | - | - | - | - | 214.26 | Upgrade
|
| Operating Expenses | 140.39 | 119.9 | 121.67 | 121.45 | 115.11 | 316.27 | Upgrade
|
| Operating Income | -406.98 | -391.49 | -389.05 | -378.42 | -335.92 | -316.27 | Upgrade
|
| Interest & Investment Income | 38.69 | 33.34 | 12.79 | 0.84 | 6.61 | 14.86 | Upgrade
|
| Other Non Operating Income (Expenses) | 6.58 | 6.06 | 16.6 | 21.07 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -361.71 | -352.09 | -359.65 | -356.51 | -329.31 | -301.41 | Upgrade
|
| Other Unusual Items | 889.14 | - | 127.85 | - | - | - | Upgrade
|
| Pretax Income | 727.43 | -352.09 | -231.8 | -356.51 | -329.31 | -301.41 | Upgrade
|
| Income Tax Expense | 53.12 | - | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | 674.31 | -352.09 | -231.8 | -356.51 | -329.31 | -301.41 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | 1,961 | 1.94 | -110.06 | Upgrade
|
| Net Income | 674.31 | -352.09 | -231.8 | 1,605 | -327.37 | -411.47 | Upgrade
|
| Net Income to Common | 674.31 | -352.09 | -231.8 | 1,605 | -327.37 | -411.47 | Upgrade
|
| Shares Outstanding (Basic) | 57 | 56 | 55 | 60 | 69 | 60 | Upgrade
|
| Shares Outstanding (Diluted) | 57 | 56 | 55 | 60 | 69 | 60 | Upgrade
|
| Shares Change (YoY) | 3.17% | 1.57% | -9.36% | -12.39% | 15.01% | 4.49% | Upgrade
|
| EPS (Basic) | 11.93 | -6.33 | -4.23 | 26.55 | -4.74 | -6.86 | Upgrade
|
| EPS (Diluted) | 11.80 | -6.33 | -4.23 | 26.55 | -4.74 | -6.86 | Upgrade
|
| Free Cash Flow | -330.11 | -297.06 | -314.36 | -413.06 | -304.87 | -382.65 | Upgrade
|
| Free Cash Flow Per Share | -5.77 | -5.34 | -5.74 | -6.83 | -4.42 | -6.38 | Upgrade
|
| Operating Margin | -1238.10% | -1459.52% | -2732.07% | - | - | - | Upgrade
|
| Profit Margin | 2051.38% | -1312.63% | -1627.82% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -1004.27% | -1107.49% | -2207.58% | - | - | - | Upgrade
|
| EBITDA | -401.29 | -384.86 | -380.48 | -369.18 | -326.13 | -308.18 | Upgrade
|
| D&A For EBITDA | 5.69 | 6.62 | 8.56 | 9.24 | 9.79 | 8.09 | Upgrade
|
| EBIT | -406.98 | -391.49 | -389.05 | -378.42 | -335.92 | -316.27 | Upgrade
|
| Revenue as Reported | 32.87 | 26.82 | 14.24 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.